Published in Infect Immun on August 01, 2003
Candida biofilms: an update. Eukaryot Cell (2005) 3.58
Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun (2004) 3.21
Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother (2006) 2.68
Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot Cell (2004) 2.61
Efflux-mediated antifungal drug resistance. Clin Microbiol Rev (2009) 2.44
Genetic control of Candida albicans biofilm development. Nat Rev Microbiol (2010) 2.39
Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother (2006) 2.18
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog (2012) 1.88
Alternative mating type configurations (a/α versus a/a or α/α) of Candida albicans result in alternative biofilms regulated by different pathways. PLoS Biol (2011) 1.84
Fungal echinocandin resistance. Fungal Genet Biol (2009) 1.78
Fungal biofilm resistance. Int J Microbiol (2012) 1.73
Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis (2010) 1.68
A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc Natl Acad Sci U S A (2005) 1.67
Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother (2008) 1.62
Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun (2010) 1.56
Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog (2011) 1.53
cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother (2005) 1.48
Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother (2010) 1.48
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Time course global gene expression analysis of an in vivo Candida biofilm. J Infect Dis (2009) 1.39
Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob Agents Chemother (2004) 1.38
Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. Eukaryot Cell (2011) 1.35
Alcohol dehydrogenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. Infect Immun (2006) 1.33
Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob Agents Chemother (2010) 1.32
Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology (2008) 1.28
Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother (2007) 1.28
Antifungal drug resistance of oral fungi. Odontology (2010) 1.21
Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet (2013) 1.20
Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J Clin Microbiol (2011) 1.18
The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell (2010) 1.16
Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence (2013) 1.15
Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiol (2014) 1.14
Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species. Antimicrob Agents Chemother (2008) 1.13
Novel entries in a fungal biofilm matrix encyclopedia. MBio (2014) 1.13
Mechanisms of Candida biofilm drug resistance. Future Microbiol (2013) 1.13
Candida albicans Biofilms and Human Disease. Annu Rev Microbiol (2015) 1.11
Flo11p, drug efflux pumps, and the extracellular matrix cooperate to form biofilm yeast colonies. J Cell Biol (2011) 1.08
Correlation between biofilm formation and the hypoxic response in Candida parapsilosis. Eukaryot Cell (2009) 1.06
Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob Agents Chemother (2008) 1.06
Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob Agents Chemother (2004) 1.02
Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother (2011) 1.01
Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother (2009) 0.97
Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. Microbiology (2011) 0.97
Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother (2011) 0.95
High-throughput nano-biofilm microarray for antifungal drug discovery. MBio (2013) 0.94
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Community participation in biofilm matrix assembly and function. Proc Natl Acad Sci U S A (2015) 0.92
Fungal biofilms, drug resistance, and recurrent infection. Cold Spring Harb Perspect Med (2014) 0.91
Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob Agents Chemother (2013) 0.91
The effect of biomaterials and antifungals on biofilm formation by Candida species: a review. Eur J Clin Microbiol Infect Dis (2012) 0.89
Protein O-mannosyltransferase isoforms regulate biofilm formation in Candida albicans. Antimicrob Agents Chemother (2006) 0.89
Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. Invest Ophthalmol Vis Sci (2012) 0.88
Microbial efflux pump inhibition: tactics and strategies. Curr Pharm Des (2011) 0.88
Update on Antifungal Drug Resistance. Curr Clin Microbiol Rep (2015) 0.87
In vitro biofilm activity of non-Candida albicans Candida species. Curr Microbiol (2010) 0.86
Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect (2016) 0.85
Lipids of Candida albicans and their role in multidrug resistance. Curr Genet (2013) 0.84
In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob Agents Chemother (2012) 0.83
Host Contributions to Construction of Three Device-Associated Candida albicans Biofilms. Infect Immun (2015) 0.82
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. Microbiol Spectr (2015) 0.81
Nylon-3 polymers active against drug-resistant Candida albicans biofilms. J Am Chem Soc (2015) 0.81
Candida albicans Biofilm Development and Its Genetic Control. Microbiol Spectr (2015) 0.81
Yeast biofilm colony as an orchestrated multicellular organism. Commun Integr Biol (2012) 0.81
Photodynamic inactivation of biofilm: taking a lightly colored approach to stubborn infection. Expert Rev Anti Infect Ther (2013) 0.81
The effect of antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida species induced biofilms. Saudi Pharm J (2013) 0.80
Rat indwelling urinary catheter model of Candida albicans biofilm infection. Infect Immun (2014) 0.80
In vitro damage of Candida albicans biofilms by chitosan. Exp Ther Med (2014) 0.80
Stimulation of superoxide production increases fungicidal action of miconazole against Candida albicans biofilms. Sci Rep (2016) 0.80
The Host's Reply to Candida Biofilm. Pathogens (2016) 0.79
Gentian violet exhibits activity against biofilms formed by oral Candida isolates obtained from HIV-infected patients. Antimicrob Agents Chemother (2011) 0.79
Detection of inhibitors of Candida albicans Cdr transporters using a diS-C3(3) fluorescence. Front Microbiol (2015) 0.79
A Putative Mitochondrial Iron Transporter MrsA in Aspergillus fumigatus Plays Important Roles in Azole-, Oxidative Stress Responses and Virulence. Front Microbiol (2016) 0.78
Plasma membrane lipids and their role in fungal virulence. Prog Lipid Res (2015) 0.78
A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates. Antimicrob Agents Chemother (2016) 0.77
In vivo inhibitory effect on the biofilm formation of Candida albicans by liverwort derived riccardin D. PLoS One (2012) 0.77
Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase. BMC Microbiol (2014) 0.77
From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr (2015) 0.76
New strategic insights into managing fungal biofilms. Front Microbiol (2015) 0.76
Delicate Metabolic Control and Coordinated Stress Response Critically Determine Antifungal Tolerance of Candida albicans Biofilm Persisters. Antimicrob Agents Chemother (2015) 0.76
Candida Biofilms: Development, Architecture, and Resistance. Microbiol Spectr (2015) 0.76
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis. Front Microbiol (2017) 0.75
The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn. Virulence (2016) 0.75
Virulence of Candida albicans isolated from HIV infected and non infected individuals. Springerplus (2015) 0.75
Chitosan-Based Nanomedicine to Fight Genital Candida Infections: Chitosomes. Mar Drugs (2017) 0.75
Resistance of Candida albicans Biofilms to Drugs and the Host Immune System. Jundishapur J Microbiol (2016) 0.75
Garcinia xanthochymus Benzophenones Promote Hyphal Apoptosis and Potentiate Activity of Fluconazole against Candida albicans Biofilms. Antimicrob Agents Chemother (2015) 0.75
Biosynthesis of micro- and nanocrystals of Pb (II), Hg (II) and Cd (II) sulfides in four Candida species: a comparative study of in vivo and in vitro approaches. Microb Biotechnol (2017) 0.75
Susceptibility of Candida albicans and Candida dubliniensis to Photodynamic Therapy Using Four Dyes as the Photosensitizer. J Dent (Shiraz) (2016) 0.75
The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. BMC Microbiol (2016) 0.75
Antifungal Activity of the Biphosphinic Cyclopalladate C7a against Candida albicans Yeast Forms In Vitro and In Vivo. Front Microbiol (2017) 0.75
Pleiotropic effects of the vacuolar ABC transporter MLT1 of Candida albicans on cell function and virulence. Biochem J (2016) 0.75
An Optimized Lock Solution Containing Micafungin, Ethanol and Doxycycline Inhibits Candida albicans and Mixed C. albicans - Staphyloccoccus aureus Biofilms. PLoS One (2016) 0.75
Fungal Biofilms: Targets for the Development of Novel Strategies in Plant Disease Management. Front Microbiol (2017) 0.75
A common mechanism involving the TORC1 pathway can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations. Sci Rep (2016) 0.75
Principles of a New Protocol for Prediction of Azole Resistance in Candida albicans Infections on the Basis of ERG11 Polymorphisms. Curr Microbiol (2016) 0.75
The lipopeptides pseudofactin II and surfactin effectively decrease Candida albicans adhesion and hydrophobicity. Antonie Van Leeuwenhoek (2015) 0.75
In vitro inhibitory activities of magnolol against Candida spp. Drug Des Devel Ther (2017) 0.75
Persistence and drug tolerance in pathogenic yeast. Curr Genet (2016) 0.75
Development and regulation of single- and multi-species Candida albicans biofilms. Nat Rev Microbiol (2017) 0.75
Bacterial biofilms: a common cause of persistent infections. Science (1999) 40.82
Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev (2002) 17.58
Correlation between protein and mRNA abundance in yeast. Mol Cell Biol (1999) 16.95
Biofilm formation as microbial development. Annu Rev Microbiol (2000) 13.33
Antibiotic resistance of bacteria in biofilms. Lancet (2001) 12.62
Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol (2001) 11.67
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 7.44
Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol (2001) 6.98
Genetic approaches to study of biofilms. Methods Enzymol (1999) 6.78
Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother (1997) 5.66
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 5.51
Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother (2001) 4.89
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother (2002) 4.52
Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother (2000) 4.41
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother (1996) 4.24
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell (1991) 3.95
Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet (1995) 3.85
Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol (2002) 3.57
Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res (2001) 3.57
Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother (2002) 3.18
Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun (2002) 2.94
A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2000) 2.91
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother (1996) 2.84
Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol (1999) 2.32
Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med (1996) 2.09
Candida albicans ALS1: domains related to a Saccharomyces cerevisiae sexual agglutinin separated by a repeating motif. Mol Microbiol (1995) 2.08
Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2001) 1.96
Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother (1996) 1.89
Predictors of adverse outcome in cancer patients with candidemia. Am J Med (1998) 1.89
Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeasts. Appl Environ Microbiol (1997) 1.88
Role of biofilms in antimicrobial resistance. ASAIO J (2001) 1.71
Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab (2001) 1.58
Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections. Acta Odontol Scand (1990) 1.56
Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter. Mol Biol Cell (1998) 1.55
The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J Med Vet Mycol (1987) 1.49
Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother (2000) 1.44
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother (1997) 1.41
In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Chemother (2002) 1.38
Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob Agents Chemother (2002) 1.36
Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4. Crit Rev Microbiol (1987) 1.33
Resistance of Streptococcus sanguis biofilms to antimicrobial agents. APMIS (1996) 1.24
Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob Agents Chemother (2002) 1.18
An evaluation of the potential of the multiple antibiotic resistance operon (mar) and the multidrug efflux pump acrAB to moderate resistance towards ciprofloxacin in Escherichia coli biofilms. J Antimicrob Chemother (2000) 1.17
The lipid composition and permeability to the triazole antifungal antibiotic ICI 153066 of serum-grown mycelial cultures of Candida albicans. J Gen Microbiol (1989) 1.16
Histopathology, immunology, and serology of oral yeast infections. Diagnosis of oral candidosis. Acta Odontol Scand (1990) 1.08
Reference high-efficiency nonpolar packed columns for the gas-liquid chromatography of nanogram amounts of steroids. I. Retention time data. J Chromatogr (1968) 1.04
Efflux-mediated resistance to fluconazole could be modulated by sterol homeostasis in Saccharomyces cerevisiae. J Antimicrob Chemother (2000) 0.99
Subinhibitory concentration of octenidine and pirtenidine: influence on the lipid and sterol contents of Candida albicans. Chemotherapy (1992) 0.91
Antifungal therapy in the oral cavity. Periodontol 2000 (1996) 0.86
P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. Eur J Pharm Sci (2000) 0.84
Catheter-related bloodstream infections in HIV-infected patients. Ann N Y Acad Sci (2001) 0.82
Multiple drug resistance in Candida albicans. Acta Biochim Pol (1995) 0.80
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Distinct roles for Dectin-1 and TLR4 in the pathogenesis of Aspergillus fumigatus keratitis. PLoS Pathog (2010) 1.84
RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology (2004) 1.79
Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother (2004) 1.73
Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs (2004) 1.69
In vitro growth and analysis of Candida biofilms. Nat Protoc (2008) 1.67
Candida biofilm resistance. Drug Resist Updat (2004) 1.65
Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother (2003) 1.60
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis (2004) 1.51
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis (2011) 1.42
Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. Infect Dis Clin North Am (2003) 1.39
Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology (2007) 1.39
Candida biofilm: a well-designed protected environment. Med Mycol (2005) 1.37
Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions. Antimicrob Agents Chemother (2007) 1.36
Alcohol dehydrogenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. Infect Immun (2006) 1.33
Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol (2004) 1.32
MyD88 regulation of Fusarium keratitis is dependent on TLR4 and IL-1R1 but not TLR2. J Immunol (2008) 1.19
Increased resistance of contact lens-related bacterial biofilms to antimicrobial activity of soft contact lens care solutions. Cornea (2009) 1.18
Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother (2011) 1.16
Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun (2007) 1.16
In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients. Int J Antimicrob Agents (2008) 1.16
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother (2008) 1.11
Characterization of bacterial communities in venous insufficiency wounds by use of conventional culture and molecular diagnostic methods. J Clin Microbiol (2011) 1.06
The RodA hydrophobin on Aspergillus fumigatus spores masks dectin-1- and dectin-2-dependent responses and enhances fungal survival in vivo. J Immunol (2013) 1.03
Novel antiseptic urinary catheters for prevention of urinary tract infections: correlation of in vivo and in vitro test results. Antimicrob Agents Chemother (2009) 1.02
Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother (2003) 1.02
A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J Am Acad Dermatol (2005) 1.01
Fungal biofilms and antimycotics. Curr Drug Targets (2005) 1.01
Mechanisms of fungal resistance: an overview. Drugs (2002) 0.99
Modification of surface properties of biomaterials influences the ability of Candida albicans to form biofilms. Appl Environ Microbiol (2005) 0.99
A murine model of contact lens-associated fusarium keratitis. Invest Ophthalmol Vis Sci (2009) 0.98
Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. Microbiology (2011) 0.97
Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. Int J Med Microbiol (2009) 0.95
Single-step PCR using (GACA)4 primer: utility for rapid identification of dermatophyte species and strains. J Clin Microbiol (2008) 0.93
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother (2011) 0.93
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob Agents Chemother (2008) 0.92
Photodynamic therapy with Pc 4 induces apoptosis of Candida albicans. Photochem Photobiol (2011) 0.92
Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents (2008) 0.91
Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces. J Infect Dis (2009) 0.91
Differential expression of Candida albicans phospholipase B (PLB1) under various environmental and physiological conditions. Microbiology (2003) 0.90
Cutaneous hypersensitivity to Candida albicans in idiopathic vulvodynia. Contact Dermatitis (2005) 0.90
Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. Med Mycol (2004) 0.89
Characterization of fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. Invest Ophthalmol Vis Sci (2012) 0.88
The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. Biomaterials (2011) 0.88
Iron deprivation induces EFG1-mediated hyphal development in Candida albicans without affecting biofilm formation. FEMS Yeast Res (2008) 0.88
Central venous catheter-associated Nocardia bacteremia in cancer patients. Emerg Infect Dis (2011) 0.86
Shear stress modulates the thickness and architecture of Candida albicans biofilms in a phase-dependent manner. Mycoses (2008) 0.84
Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes. J Clin Microbiol (2008) 0.82
Disruption of the ECM33 gene in Candida albicans prevents biofilm formation, engineered human oral mucosa tissue damage and gingival cell necrosis/apoptosis. Mediators Inflamm (2012) 0.80
Disruption of sphingolipid biosynthetic gene IPT1 reduces Candida albicans adhesion and prevents activation of human gingival epithelial cell innate immune defense. Med Mycol (2010) 0.80
Gentian violet exhibits activity against biofilms formed by oral Candida isolates obtained from HIV-infected patients. Antimicrob Agents Chemother (2011) 0.79
Efficacy of care solutions against contact lens-associated Fusarium biofilms. Optom Vis Sci (2012) 0.79
Cutaneous hypersensitivity to Malassezia sympodialis and dust mite in adult atopic dermatitis with a textile pattern. Contact Dermatitis (2006) 0.79
Candida albicans RHO1 is required for cell viability in vitro and in vivo. FEMS Yeast Res (2002) 0.78
Animal models to investigate fungal biofilm formation. Methods Mol Biol (2014) 0.78
Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida biofilms. J Antimicrob Chemother (2011) 0.77
A rabbit model for evaluation of catheter-associated fungal biofilms. Virulence (2011) 0.77
Diagnosis and management of Enterococcus spp infections during rehabilitation of cold-stunned Kemp's ridley turtles (Lepidochelys kempii): 50 cases (2006-2012). J Am Vet Med Assoc (2014) 0.76
Characterization and partial purification of Candida albicans Secretory IL-12 Inhibitory Factor. BMC Microbiol (2008) 0.76
Candida Biofilms: Development, Architecture, and Resistance. Microbiol Spectr (2015) 0.76
Problem doctors: is there a system-level solution? Ann Intern Med (2006) 0.75
Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants. AIDS (2017) 0.75
The natural diyne-furan fatty acid EV-086 is an inhibitor of fungal delta-9 fatty acid desaturation with efficacy in a model of skin dermatophytosis. Antimicrob Agents Chemother (2013) 0.75
In vitro effect of over-the-counter probiotics on the ability of Candida albicans to form biofilm on denture strips. J Dent Hyg (2014) 0.75
The mycobiome in HIV. Curr Opin HIV AIDS (2017) 0.75